Member Info for OAPK20

3 months ??? You should watch Goldrush on Discovery. Takes them a week to work out recovery per yard of material run.

;-)

Think there’s a chance of drawdown

If you believe Widdy’s back story and Widdy’s luck then it’ll be them averaging down :-)

Mmmh. Do they have a platform ? Is it with a multi billion dollar company ?

“Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of using the Simple Western platform from ProteinSimple (a Bio-Techne brand) for high throughput detection of the CIZ1B cancer biomarker which may be useful in the detection of early-stage lung cancer.”

“ Will Geist, President of Bio-Techne's Protein Sciences Segment, commented: " We are pleased that Cizzle has chosen the Simple Western platform for the development of its novel biomarker. The automation, sensitivity, small sample input and quantitative nature of the Simple Western system makes it ideal for supporting an assay of this nature. We are excited about the progress so far and hopeful Simple Western can aid in making such a life-saving innovation available to the patients that need it."”

Just a thought …..

Spread closing upwards.

This practice needs banned.

Any thoughts on whether there’s any sort of update before end of April ?

Wouldn’t be surprised if there wasn’t,

“ CorePath is a specialist oncology reference laboratory bringing together leading clinicians, scientists, academic affiliates and state of the art facilities and will be responsible for all activities in the USA including development, clinical trials and test validation for clinical use “

Remember 6th May 2022 RNS…..

[ CorePath ] intends to [ develop ] and offer a clinical laboratory test throughout the USA using the Company's proprietary technology

-- Proposed 15% royalty and royalty sharing arrangements for the Company over all offering of products and services using CIZ1B via CorePath in the USA

-- [ Initial pilots planned ]

Anyone tracking the Optical Sorter shipment. Has it arrived or due to arrive in port soon….

Never mind a Golden cross when an RNS lands to confirm the CIZ1b biomarker blood test for Lung cancer is commercially available, in the US via CorePath, in conjunction with BioTechne’s ProtienSimple platform “ for high throughput detection of the CIZ1B cancer biomarker which may be useful in the detection of early-stage lung cancer.”

Then China …..

Better brace yourself for the Telegram pumpers then.

The Selling Securityholders may offer, sell, or distribute all or a portion of the securities hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices.

Tanked again. CIZ need to provide a progress update Q1.

3,250,000 / 363,841,773 = 0.00893245.

Reckon the 0.9p is already priced into the sp.

NEED AN UPDATE ON CLINICAL TRIAL AND COMMERCIALISATION.

Patience needed.

“GEM it’s URA we’ve started mining and found some Emeralds can you sell them at auction ?”

“Don’t know it’s really difficult”

Highlights: August/September 2023 - Commercial Quality Emerald Auction

-- Total auction revenues of USD 25.5 million

-- 43 lots were offered for sale, of which all 43 were sold (100%)

-- Average price of USD 7.51 per carat

Is that how difficult it is to get someone to sell something on your behalf?

Holdings RNS 31 March 2022 shows they sold their remaining holding.

Glad we have the CEO we have.

CIZ paid out £255,000 cash for economic interest in AZD1656. Then get paid £200,000 by SGSC so £55,000 paid out and the 5% interest was settled with issuing shares in CIZ to a value of £1,880,000.

They executed the put and received £3,250,000 worth NASDAQ shares in CDT at $10 a share.

Maybe think more of how much potential profit could be made from a £55,000 cash outlay for the economic interest in AZD1656.

20 September 2021

“SGSC to grant Cizzle Biotechnology potential future royalty payments from the commercialisation of St George Street's therapeutic asset AZD1656 of up to GBP5 million, plus potentially further payments from the use of a companion diagnostic.”

“Under the full commercial contract entered into, in consideration of the potential future royalty stream from the commercialisation of AZD1656 , Cizzle Biotechnology is to pay GBP135,000 to SGSC.”

22 October 2021

“Research and Development agreement worth up to GBP1 million signed for potential autoimmune disease testing and possible additional companion diagnostics.”

“SGSC will pay Cizzle Biotechnology GBP200,000 upfront on commencement of the project and then further milestone payments totalling up to GBP1 million. “

14 February 2022

Agreement with Conduit and SGSC to acquire a 5% economic interest for a total consideration of GBP1.88 million, to be settled in new Cizzle ordinary shares at a price of 4.0p per share, a 56.9% premium to the closing mid-market price on 11 February 2022

“The Agreement is in addition to the Company's existing interest in AZD 1656 as announced on 20 September 2021”

29 September 2022

has settled the remaining consideration of GBP880,000 due under the Agreement through the issue of 22,000,000 new ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at 4.0p per share (the "Agreement Shares") to Conduit.

19 December 2022

“Put Option for Sale of Economic Interest and Royalty Sharing Agreement in AZD1656”

“Cizzle has agreed to pay Conduit GBP120,000 in cash as the premium for the Option”

If you agree to receive shares in a company to the value of £3.25M and they are now worth £2.15M please would you consider yourself to be “up” ?

Same RNS.

Cizzle Biotechnology Holdings plc, the UK based diagnostics developer, is pleased to announce that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of the AZD 1656 asset to treat inflammatory pulmonary and cardiovascular disease (the "Economic Interest"); and (ii) its royalty sharing agreement with St George Street Capital ("SGSC"), the UK-based biomedical charity (the "Royalty Sharing Agreement') to Conduit Pharmaceuticals Limited ("Conduit") for a total consideration of GBP3.25 million to be satisfied through the issuance of new shares in Conduit (the "Option").